Sheybani Lab Research

Working at the nexus of therapeutic ultrasound, advanced imaging, and tumor immunology to design and deploy precision cancer immunotherapy paradigms.

Dr. Sheybani leads a translational research program centered on innovating tools and paradigms for non-invasive precision cancer management. Specifically, her group seeks to advance the role of focused ultrasound (FUS) - a disruptive, emerging strategy for non-invasive, non-ionizing, and precisely targeted deposition of acoustic energy into tumor tissues – for immuno-modulation and immunotherapy delivery in solid cancers of the brain and periphery (e.g. glioblastoma, metastatic breast cancer). With the goal of ushering image-guided therapies like FUS into the burgeoning era of precision immuno-oncology, Dr. Sheybani’s lab also applies approaches in systems biology and imaging informatics to advance the role of other non-invasive strategies like liquid biopsy and multimodality imaging techniques (e.g. MRI, immuno-PET), respectively, with the intent of informing risk stratification, therapeutic monitoring, and individualized treatment paradigms involving FUS and/or cancer immunotherapy. The work of the Sheybani lab interfaces closely with multiple ongoing clinical trials at UVA that are evaluating FUS immunotherapy in metastatic breast cancer and other solid tumor settings.

 

Publications

Review Sheybani Lab publications on GOOGLE SCHOLAR